Nitric oxide nanoparticles: Pre-clinical utility as a therapeutic for intramuscular abscesses

Virulence

Volumn 3, Issue 1, 2012, Pages 62-67

  Schairer, David ^a   Martinez, Luis R ^b,c   Blecher, Karin ^a   Chouake, Jason ^a   Nacharaju, Parimala ^b   Gialanella, Philip ^a   Friedman, Joel M ^b   Nosanchuk, Joshua D ^a,b   Friedman, Adam ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

MRSA; Nanotechnology; Nitric oxide; Pyomyositis

Indexed keywords

NANOPARTICLE; NITRIC OXIDE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL SURVIVAL; CONTROLLED STUDY; HOST RESISTANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PYOMYOSITIS; SKIN ABSCESS; SOFT TISSUE INFECTION;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MURINAE;

EID: 84858229896     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.3.1.18816     Document Type: Article

References (31)

1. Olson DP, Soares S, Kanade SV. Community-acquired MRSA pyomyositis: case report and review of the literature. J Trop Med 2011; 2011:970848; PMID:21461362
2. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO, Jr., Kaplan SL. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin- resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43:953-960; PMID:16983604; http://dx.doi.org/10.1086/507637
3. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis 2010; 50(Suppl 1):S4-S9;PMID:20067391; http://dx.doi.org/10.1086/647937
4. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-164; PMID: 18171244; http://dx.doi.org/10.1086/524891
5. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997; 99:2818-2825; PMID: 9185502; http://dx.doi.org/10.1172/JCI119473
6. Han G, Zippin JH, Friedman A. From Bench to Bedside: The Therapeutic Potential of Nitric Oxide in Dermatology. J Drugs Dermatol 2009; 8:586-594;PMID:19537386
7. Jones ML, Ganopolsky JG, Labbe A, Prakash S. A novel nitric oxide producing probiotic patch and its antimicrobial efficacy: preparation and in vitro analysis. Appl Microbiol Biotechnol 2010; 87:509-516;PMID:20300748; http://dx.doi.org/10.1007/s00253-010-2490-x
8. Seabra AB, Martins D, Simoes M, da Silva R, Brocchi M, de Oliveira MG. Antibacterial nitric oxide-releasing polyester for the coating of blood-contacting artificial materials. Artif Organs 2010; 34:E204-E214; PMID: 20497163; http://dx.doi.org/10.1111/j.1525-1594.2010.00998.x
9. Major TA, Panmanee W, Mortensen JE, Gray LD, Hoglen N, Hassett DJ. Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions. Antimicrob Agents Chemother 2010; 54:4671-4677;PMID:20696868; http://dx.doi.org/10.1128/AAC.00379-10
10. Mihu MR, Sandkovsky U, Han G, Friedman JM, Nosanchuk JD, Martinez LR. The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections. Virulence 2010; 1:62-67; PMID:21178416; http://dx.doi.org/10.4161/viru.1.2.10038
11. Hetrick EM, Shin JH, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 2009; 30:2782-2789; PMID:19233464; http://dx.doi.org/10.1016/j.biomaterials.2009.01.052
12. Martinez LR, Han G, Chacko M, Mihu MR, Jacobson M, Gialanella P, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against staphylococcus aureus skin infection. J Invest Dermatol 2009; 129:2463-2469; PMID:19387479; http://dx.doi.org/10.1038/jid.2009.95
13. Hetrick EM, Shin JH, Stasko NA, Johnson CB, Wespe DA, Holmuhamedov E, et al. Bactericidal efficacy of nitric oxide-releasing silica nanoparticles. ACS Nano 2008; 2:235-246; PMID:19206623; http://dx.doi.org/10.1021/nn700191f
14. Friedman A, Friedman J. New biomaterials for the sustained release of nitric oxide: past, present and future. Expert Opin Drug Deliv 2009; 6:1113-1122;PMID:19663720; http://dx.doi.org/10.1517/17425240903196743
15. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles: Characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008; 19:12-20; PMID:18457680; http://dx.doi.org/10.1016/j.niox.2008.04.003
16. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, et al. Upregulation of hosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001; 104:2338-2343; PMID: 11696475; http://dx.doi.org/10.1161/hc4401.098432
17. Friedman A, Blecher K, Sanchez D, Tuckman-Vernon C, Gialanella P, Friedman JM, et al. Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence 2011; 2:217-221; PMID:21577055; http://dx.doi.org/10.4161/viru.2.3.16161
18. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. PLoS ONE 2009; 4:e7804; PMID:19915659; http://dx.doi.org/10.1371/journal.pone.0007804
19. Han G, Friedman AJ, Friedman JM. Nitric oxide releasing nanoparticle synthesis and characterization. Methods Mol Biol 2011; 704:187-195; PMID:21161638; http://dx.doi.org/10.1007/978-1-61737-964-2_14
20. Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, et al. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54:116-125; PMID:19884364; http://dx.doi.org/10.1128/AAC.00642-09
21. Patel MV, De Souza NJ, Gupte SV, Jafri MA, Bhagwat SS, Chugh Y, et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother 2004; 48:4754-4761; PMID:15561853; http://dx.doi.org/10.1128/AAC.48.12.4754-4761.2004
22. Tavares AF, Nobre LS, Melo AM, Saraiva LM. A novel nitroreductase of Staphylococcus aureus with S-nitrosoglutathione reductase activity. J Bacteriol 2009; 191:3403-3406; PMID:19286809; http://dx.doi.org/10.1128/JB.00022-09
23. Farokhzad OC. Nanotechnology for drug delivery: the perfect partnership. Expert Opin Drug Deliv 2008; 5:927-929; PMID:18754745; http://dx.doi.org/10.1517/17425247.5.9.927
24. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3:16-20; PMID: 19206243; http://dx.doi.org/10.1021/nn900002m
25. Friedman A, Friedman J. New biomaterials for the sustained release of nitric oxide: past, present and future. Expert Opin Drug Deliv 2009; 6:1113-1122; PMID:19663720; http://dx.doi.org/10.1517/17425240903196743
26. Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981; 3(Suppl):S200-S204; PMID:7043707
27. Mowbray M, Tan X, Wheatley PS, Rossi AG, Morris RE, Weller RB. Topically applied nitric oxide induces T-lymphocyte infiltration in human skin, but minimal inflammation. J Invest Dermatol 2008; 128:352-360;PMID:17914444; http://dx.doi.org/10.1038/sj.jid.5701096
28. Dal Secco D, Paron JA, de Oliveira SH, Ferreira SH, Silva JS, Cunha Fde Q. Neutrophil migration in inflammation: nitric oxide inhibits rolling, adhesion and induces apoptosis. Nitric Oxide 2003; 9:153-164;PMID:14732339; http://dx.doi.org/10.1016/j.niox.2003.11.001
29. Breen JO. Skin and soft tissue infections in immunocompetent patients. Am Fam Physician 2010; 81:893-899; PMID:20353147
30. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009; 69:1879-1901; PMID:19747006; http://dx.doi.org/10.2165/11315690-000000000-00000
31. Spellberg B. The antibiotic crisis: can we reverse 65 years of failed stewardship? Arch Intern Med 2011; 171:1080-1081; PMID:21357798; http://dx.doi.org/10.1001/archinternmed.2011.26